IP Library Granted Patent US 10,195,149
Granted Patent B2
US 10,195,149 · App. 14/278,035 · Granted Feb 5, 2019

Continuous process for preparing microspheres and microspheres prepared thereby

Inventors: Yi Mi Kim (Yongin-si, KR); Sun Kyung Lim (Yongin-si, KR); Mi Ran Park (Seoul, KR); Young Joon Park (Seoul, KR); Seung Hee Baek (Suwon-si, KR); Hyun Woo Shin (Seoul, KR)
Assignee: CJ HEALTHCARE CORPORATION
A61K9/1682A61K9/1647A61K9/1694A61K38/22B01F3/0807B01F5/04B01F15/0222B01F2215/0032
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,195,149
App. No.
14/278,035
Filed
May 15, 2014
Granted
Feb 5, 2019
Kind
B2
Art Unit
1615
USPC
424/489
Abstract

The present invention relates to a continuous process for preparing microspheres and microspheres prepared thereby, and in particular, a process for preparing microspheres comprising steps of injecting a first emulsion and a second emulsion at the same time to form microspheres instantaneously, applying high pressure to the microspheres formed, and injecting the microspheres into an agitator, wherein the steps can be carried out continuously, and microspheres prepared thereby. When microspheres are prepared using the method of the present invention, scale variables, which have been the biggest disadvantage in existing preparation methods of microspheres, can be significantly reduced, drug encapsulation efficiency can be improved, and small and uniform particles can be obtained.

Claims (16)

1. A process for preparing microspheres in which a physiologically active substance is encapsulated in a carrier polymer using a double emulsification method, comprising:

dispersing or mixing a carrier polymer dissolved in a solvent and a physiologically active substance to form a first emulsion (Step 1);

continuously mixing a certain amount of each of the first emulsion and a second solution in which a surfactant is dissolved to form a second emulsion (Step 2); and

continuously flowing the second emulsion through a high pressure homogenizer or a high pressure pump and applying pressure of 500 psi to 30,000 psi to the second emulsion before the polymer is cured as the solvent in the first emulsion is evaporated or removed, thereby controlling the size of microspheres before the polymer is cured as the solvent in the first emulsion is evaporated or removed (Step 3).

2. The process of claim 1 , further comprising the step of:

stirring the second emulsion (Step 4) after the Step 3.

3. The process of claim 1 , wherein Step 2 is performed by continuously transferring a certain amount of each of the first emulsion and the second solution into a reactor, in which the second emulsion is formed, by a liquid transfer pump, and by mixing the first emulsion and the second solution to form the second emulsion.

4. The process of claim 3 , wherein the reactor has a mesh net installed on the inside, and the second emulsion is formed after the first emulsion and the second solution pass through the mesh net.

5. The process of claim 4 , wherein the mesh net has a pore size ranging from 1 μm to 50 μm.

6. The process of claim 2 , wherein the Step 4 is performed by continuously injecting the second emulsion from a reactor, in which the second emulsion is formed, into an agitator, and stirring the second emulsion in the agitator.

7. The process of claim 6 , wherein the rate of injecting the second emulsion into the agitator is the same as the rate of supplying the first emulsion and the second solution to the reactor.

8. The process of claim 6 , wherein a means to inject the second emulsion into the agitator includes a high pressure pump or a liquid transfer pump.

9. The process of claim 1 , wherein the physiologically active substance is any one or more selected from the group consisting of a luteinizing hormone-release hormone (LHRH) homologue, a peptide, and salts thereof.

10. The process of claim 9 , wherein the physiologically active substance is any one or more selected from the group consisting of goserelin, leuprolide acetate, triptorelin, buserelin, nafarelin, cetrorelix and argitide.

11. The process of claim 1 , wherein the carrier polymer is a biodegradable polymer.

12. The process of claim 11 , wherein the carrier polymer is one or more selected from the group consisting of polylactide, polyglycolide, and poly(lactide-co-glycolide), polyorthoester, polyanhydride, polyamino acid, polyhydroxybutyric acid, polycaprolactone, polyalkyl carbonate, lipid, fatty acid, wax, albumin, gelatin, collagen, fibric acid, alginic acid, chitin, chitosan, dextran, hyaluronic acid and starch.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2014
From: CJ CHEILJEDANG CORPORATION
To: CJ HEALTHCARE CORPORATION
Reel/Frame 034305/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2014
From: KIM, YI MI; LIM, SUN KYUNG; PARK, MI RAN; PARK, YOUNG JOON; BAEK, SEUNG HEE; SHIN, HYUN WOO
To: CJ CHEILJEDANG CORPORATION
Reel/Frame 032901/0732 →
Priority Claims (1)
KR 10-2013-0055356 · May 15, 2013 · national
Continuity (1)
Related Publication 20140341997A1 · Nov 20, 2014